Sign in
Taking people in United StatesPhase 2/3

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Key facts

Who runs it
Crinetics Pharmaceuticals Inc.
Where
Ann Arbor, Boston, Charlottesville, Chicago, Fort Worth, Los Angeles, Minneapolis, New Brunswick, New York, Philadelphia, and San Francisco, United StatesSee the 11 sitesAlso in 12 other countries, 47 sites
Status
Recruiting
Phase
Phase 2/3
People taking part
153 people, planned
Started
22 Jan 2026
Expected to end
Mar 2030
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Atumelnant
  • Placebo
Record updated
10 November 2026

Who can take part

Age
1 year to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Part A and B participants are eligible to be included in the study only if all of the following criteria apply:
  • Male or female at birth, between 1 to <18 years of chronological age at the time of signing the Informed Consent Form (ICF)
  • Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency (21-OHD) based on standard medically accepted criteria such as elevated 17-OHP level, confirmed CYP21A2 genetic testing, positive newborn screening with confirmatory second tier testing, or cosyntropin stimulation
  • Participants must have an elevated morning serum A4 level >ULN during Screening obtained prior to morning glucocorticoid (GC) administration
  • Participants must be on a stable supraphysiologic GC replacement therapy for at least one month prior to Screening
  • Compliance, as judged per Investigator discretion, with GC replacement and mineralocorticoid replacement (if applicable) regimen documented during the Screening Period
  • Biochemical euthyroidism as determined by the Investigator; Part C inclusion criteria require participants to complete treatment in either Part A or Part B and in the Investigator's opinion it would benefit the participant to continue in Part C, regardless of age

Who cannot take part

  • Participants treated with other GCs within 30 days of Screening
  • Stress dose of GC therapy within 2 weeks of start of Screening, defined as any dose above the normal maintenance dose, including but not limited to intravenous (IV) or intramuscular (IM) hydrocortisone
  • Participants who have been dosed with an investigational drug (including atumelnant) in any prior clinical study within 60 days or 5 half-lives (whichever is longer) prior to the first dose
  • History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ
  • Part A and Part B: Individuals in Part A and Part B who meet any of the following criteria will be excluded from participation in this study:
  • Diagnosis of any form of CAH other than classic 21-OHD
  • Use of growth hormones within 1 week of start of Screening for short acting, or within 6 weeks of start of Screening for long acting
  • Use of a corticotropin-releasing factor receptor antagonist within 14 days of Screening
  • Abnormal sleep/wake cycles (as determined by the Investigator)
  • Female participants who are pregnant or lactating
  • Individuals in Part C who do not meet the Part C Inclusion Criteria

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 17 years old?

Where in United States

Also in 12 other countries, 47 sites

  • University of MichiganAnn Arbor, United StatesContact: Crinetics Clinical TrialsTaking people
  • Boston's Children's HospitalBoston, United StatesContact: Crinetics Clinical TrialsTaking people
  • University of Virginia Health SystemCharlottesville, United StatesContact: Crinetics Clinical TrialsTaking people
  • Ann and Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Crinetics Clinical TrialsTaking people
  • Cook Children's Health Care SystemFort Worth, United StatesContact: Crinetics Clinical TrialsTaking people
  • Children's Hospital Los AngelesLos Angeles, United StatesContact: Crinetics Clinical TrialsTaking people
  • University of MinnesotaMinneapolis, United StatesContact: Crinetics Clinical TrialsTaking people
  • Rutgers, Robert Wood Johnson Medical SchoolNew Brunswick, United StatesContact: Crinetics Clinical TrialsTaking people
  • Icahn School of Medicine at Mount Sinai, Mount Sinai HospitalNew York, United StatesContact: Crinetics Clinical TrialsTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Crinetics Clinical TrialsTaking people
  • UCSF Ron Conway Gateway Medical BuildingSan Francisco, United StatesContact: Crinetics Clinical TrialsTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).

The 4 groups in the trial

  • Treatment (Part A)Treatment being tested

    Open-label, semi-sequential cohorts.

    Treatment: Atumelnant

  • Active Treatment (Part B)Treatment being tested

    Randomized, Parallel Arms, Double-Blind

    Treatment: Atumelnant

  • Placebo (Part B)Placebo, for comparison

    Randomized, Parallel Arms, Double-Blind

    Treatment: Placebo

  • Open-Label Treatment (Part C)Treatment being tested

    Open-label treatment period for participants entering Part C from Part A and B.

    Treatment: Atumelnant

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension
Fit questions
Built from NCT07159841, who can take part
Record updated
10 November 2026